← Human Trials & Peer-Reviewed Studies
Increased mortality associated with growth hormone treatment in critically ill adults.
Plain-language guide to PMID 10477776 (1999): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 247 patients.
Key Facts
- PMID
- 10477776
- Journal
- The New England journal of medicine
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Takala J et al. (7 authors)
- DOI
- 10.1056/NEJM199909093411102
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
The administration of growth hormone can attenuate the catabolic response to injury, surgery, and sepsis.
Who Took Part
According to the abstract, 247 patients were involved.
By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled, multicenter and parallel-group.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
More than one site took part, so the patients came from several places.
What Was Measured
PubMed files the paper under topics including Cause of Death, Critical Care, Critical Illness, Energy Intake, Hospital Mortality, Human Growth Hormone and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 247 patients.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1999 (The New England journal of medicine), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.